Clinical Trial Update: Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes [Phase 2]

View source ↗

Summary

Phase 2 trial assessing a hydroxychloroquine-based combination against regorafenib for refractory metastatic colorectal cancer with RAS mutations; recruitment i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Colorectal Neoplasms

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• Hydroxychloroquine (hydroxychloroquine)
• METHOTREXATE (METHOTREXATE)
• Regorafenib (regorafenib)

Snippet

Sponsor: Sergey Orlov, MD | Conditions: Metastatic Colorectal Cancer (mCRC), Colorectal Neoplasms | Phase 2 | Status: RECRUITING